Dualyx is a Ghent-based biotech company that develops novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven.

Dualyx

dualyx NV focuses on the discovery and development of highly innovative biologicals for the treatment of autoimmune and rare diseases.
We aim to create long-lasting treatments for patients with a high unmet medical need.

Gemma Frisius Fund

Andera Partners

DUAL

COM:DUALYX

Dualyx